Medgenics (MDGN)

[BollixMeArse]

Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference

PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 26th Annual Piper Jaffray Healthcare Conference in New York.

The event will take place at 12:00 p.m. EST on Wednesday, December 3, 2014 at The New York Palace Hotel. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: http://www.media-server.com/m/p/67nyj8e4.

About Medgenics, Inc.

Medgenics is developing TARGT(TM) (Transduced Autologous Restorative Gene Therapy), a proprietary ex vivo gene therapy platform for the sustained production and delivery of therapeutic proteins and peptides using a patient's own tissue, for the treatment of rare and orphan diseases. For more information, visit the Company's website at www.medgenics.com.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.


Contact:
Medgenics, Inc.
John Leaman
[e-mail]
Brian Piper
[e-mail]
Stern Investor Relations
Beth DelGiacco
212-362-1200
[e-mail]